Meeting
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
Authors
Howard Kaufman
Rush University Medical Center, Chicago, IL
Howard Kaufman , Jiafeng Wang , Brendan D. Curti , Joseph Clark , Marc S. Ernstoff , Ann Silk , Janice M. Mehnert , Andrew Zloza , Joe Shih , David F. McDermott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT02203604
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3095)
DOI
10.1200/jco.2015.33.15_suppl.tps3095
Abstract #
TPS3095
Poster Bd #
417a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study.
First Author: Madeeha Ashraf
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
First Author: Maria Constantinou
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia
Poster
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal